Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Antidotes01:17

Antidotes

629
Antidotes are medicinal substances used to counteract the harmful effects of toxins or drugs in the body. They function in various ways, each uniquely designed to combat specific toxic compounds.
Specific antidotes operate by inhibiting the enzymes that control biochemical pathways, reducing the production of harmful metabolites.
An example of an antidote is atropine, which counteracts the detrimental effects of cholinesterase inhibitors. It achieves this by deactivating muscarinic receptors,...
629
Masking and Demasking Agents01:19

Masking and Demasking Agents

2.4K
EDTA titrations may necessitate masking and demasking agents to temporarily protect a particular metal ion in a mixture from the EDTA reaction. These agents facilitate the sequential analysis of the metal ions by forming stable complexes with some—but not all—metal ions during certain steps.
There are many masking agents, such as cyanide, fluoride, triethanolamine, thiourea, and 2,3-bis(sulfanyl)propan-1-ol (formerly 2,3-dimercapto-1-propanol), with the masking agent chosen based on...
2.4K
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

87
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
87
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

126
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
126
EDTA: Direct, Back-, and Displacement Titration01:30

EDTA: Direct, Back-, and Displacement Titration

2.7K
The EDTA titration types for metal ion analysis include direct titration, back-titration, and replacement titration.
Direct titration involves buffering the metal ion solution to the desired pH and directly titrating with standard EDTA until the endpoint. The optimum pH ensures a large conditional formation constant of metal−EDTA and visibility of the free indicator color in the solution. In addition, auxiliary complexing reagents are used to prevent the precipitation of metal hydroxides...
2.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Not so subclinical: Is early thyroid disease an untapped avenue to protect children from MASLD?

Hepatology (Baltimore, Md.)·2025
Same author

More than a lark? LRRK2 inhibitors to treat alpha-1 antitrypsin deficiency.

Hepatology (Baltimore, Md.)·2025
Same author

Deletion of sphingosine 1-phosphate receptor 1 in myeloid cells reduces hepatic inflammatory macrophages and attenuates MASH.

Hepatology communications·2025
Same author

Alcohol-associated liver disease: The time to act is now.

Hepatology (Baltimore, Md.)·2024
Same author

Therapeutic manipulation of the microbiome in liver disease.

Hepatology (Baltimore, Md.)·2024
Same author

Precipitous changes in nomenclature and definitions-NAFLD becomes SLD: Implications for and expectations of AASLD journals.

Clinical liver disease·2023

相关实验视频

Updated: Jun 25, 2025

Ion Mobility-Mass Spectrometry Techniques for Determining the Structure and Mechanisms of Metal Ion Recognition and Redox Activity of Metal Binding Oligopeptides
11:04

Ion Mobility-Mass Spectrometry Techniques for Determining the Structure and Mechanisms of Metal Ion Recognition and Redox Activity of Metal Binding Oligopeptides

Published on: September 7, 2019

9.2K

金属:它需要一个不同的治疗选择吗?

George W Marek1, Harmeet Malhi

  • 1Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.

Hepatology (Baltimore, Md.)
|May 31, 2024
PubMed
概括
此摘要是机器生成的。

新的指导方针将代谢功能障碍和与酒精相关的肝病 (MetALD) 定义为重叠状况. 研究正在探索MetALD的治疗方法,重点是戒断策略和脂肪性肝病有前途的药物类.

更多相关视频

Dose Uptake of Platinum- and Ruthenium-based Compound Exposure in Zebrafish by Inductively Coupled Plasma Mass Spectrometry with Broader Applications
08:46

Dose Uptake of Platinum- and Ruthenium-based Compound Exposure in Zebrafish by Inductively Coupled Plasma Mass Spectrometry with Broader Applications

Published on: April 21, 2022

2.4K
Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization
08:13

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization

Published on: December 3, 2020

4.6K

相关实验视频

Last Updated: Jun 25, 2025

Ion Mobility-Mass Spectrometry Techniques for Determining the Structure and Mechanisms of Metal Ion Recognition and Redox Activity of Metal Binding Oligopeptides
11:04

Ion Mobility-Mass Spectrometry Techniques for Determining the Structure and Mechanisms of Metal Ion Recognition and Redox Activity of Metal Binding Oligopeptides

Published on: September 7, 2019

9.2K
Dose Uptake of Platinum- and Ruthenium-based Compound Exposure in Zebrafish by Inductively Coupled Plasma Mass Spectrometry with Broader Applications
08:46

Dose Uptake of Platinum- and Ruthenium-based Compound Exposure in Zebrafish by Inductively Coupled Plasma Mass Spectrometry with Broader Applications

Published on: April 21, 2022

2.4K
Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization
08:13

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization

Published on: December 3, 2020

4.6K

科学领域:

  • 肝病学 肝病学是一种肝病学.
  • 药理学 药理学是指药理学的学科.
  • 代谢疾病 代谢疾病

背景情况:

  • 新的指导方针引入了代谢功能障碍和与酒精相关的肝病 (MetALD) 作为代谢功能障碍相关的脂肪性肝病 (MASLD) 和与酒精相关的肝病 (ALD) 的重叠.
  • 虽然许多治疗方法正在开发中,但在持续饮酒的患者中,它们的疗效和安全性在很大程度上尚未研究.
  • 了解与MASLD和MetALD相关的风险对于开发有效治疗至关重要.

研究的目的:

  • 审查目前对MASLD和MetALD内源性和外源性风险的理解.
  • 讨论MetALD的合理治疗策略,包括对酒精使用和脂肪性肝病的干预措施.
  • 确定有前途的治疗药物,并强调需要对MetALD.进行进一步研究.

主要方法:

  • 对MASLD和与酒精有关的肝病现有研究的文献综述.
  • 对脂肪性肝病的当前和正在发展的治疗策略的分析.
  • 讨论MetALD.的风险因素和潜在的治疗干预措施.

主要成果:

  • 对MetALD的治疗干预应包括生物心理社会方法,戒酒策略 (包括药物治疗),以及合理使用脂肪性肝病治疗方法.
  • 对MetALD有前途的治疗类别包括基于英克雷丁的疗法,FGF21激动剂,甲状腺激素受体β激动剂,SGLT2抑制剂和针对de novo脂质生成的药物.
  • 目前的研究主要支持葡萄糖类1受体激动剂和MASLD的PPAR-γ激动剂,对ALD的试验中药物有限. 对MetALD的最佳治疗方法尚不清楚.

结论:

  • 有效管理MetALD需要一个多方面的方法,结合生活方式干预,戒酒和向药物治疗.
  • 进一步的临床试验对于评估MASLD相关疗法的安全性和有效性在MetALD群体中至关重要.
  • 阐明MetALD的特定治疗需求对于推进治疗选择和改善患者治疗结果至关重要.